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of  the  European Regulation REACH. Much  emphasis  is  placed  on  in vitro methods 
based on subcellular mechanisms (e.g., nuclear receptor interaction), but it is necessary 





of  endocrine-targeted  tissues  (e.g.,  prostate)  and  on  functional  biomarkers  of  clinical 
relevance (e.g., PSA secretion in human prostate epithelial cells). We discuss the imple-
mentation of such functional biomarkers in the AOP context. 
Chemical  risk  assessment  addresses  the  probability 
that  a  certain  exposure  level  to  a  chemical  can  cause 
an  adverse  effect,  whose  nature  and  degree  of  sever-
ity,  including  possible  reversibility,  should  be  evaluat-
ed. The general,  internationally  accepted WHO/IPCS 
(World Health Organization/International Programme 
on Chemical Safety) definition of  adverse  effect  is  “a 
change in the morphology, physiology, growth, development, 
reproduction, or life span of an organism, system, or (sub)
population that results in an impairment of functional ca-
pacity or of the capacity to compensate for additional stress, 
or an increase in susceptibility to other influences” [1 and 
refs  therein].  This  definition  appears  straightforward; 
indeed, it can still hold true in the changing framework 

















susceptible  population  groups.  To  date  the  definition 

















genic/antiestrogenic”  action,  like  the  in vitro  estrogen 




















“endocrine disruption is just a mode-of-action that may or 
may not result in adverse effects” and that it has to be dealt 
with like other non-genotoxic agents [4]. According to 
this  viewpoint,  endocrine  disruption  is  somewhat  like 





might  be pushed quite  far  away:  a  reduction of  sper-














old,  especially  for  chemicals  interacting  with  nuclear 
receptors (NRs), thus acting through hormone mimicry 
or  antagonism.  It  assumes  that  the NR  interaction  is 
maybe a toxicologically relevant initiating event; in such 











non-monotonic  dose-response  (NMDR)  relationships 









































Mode of Action (MoA)








Molecular Docking on NRs and QSAR
STEP 2
In vitro Whole Cell Activity Assessment:
Endocrine based Screening by measurement of







using BIOMARKERS (based on clinical biomarkers)
for Human Cell Lines representing ED target tissues
• LNCaP (prostate epithelium) → PSA secretion (free e total)
• BeWo (1st trimester trophoblast) → β–hCG secretion
• HuH6 (fetal hepatocytes) → AFP secretion; steatosis
GENE REPORTER ASSAYS
based on main targeted NRs
for LIFE-EDESIA chemicals of interest
• AR-based  EURL-ECVAM TM 2010-07 or commercially available
• ER-based  OECD TG-455 or ECVAM TM2009-02/MELN 
 or commercially available
• PPAR-based Commercially available
(D)
AR: androgen receptor; ECVAM: European Centre for the Validation of Alternative Methods; ER: estrogen receptor; OECD: Organization for Economic Co-
operation and Development, PPAR: peroxisome proliferator-activated receptor; TM = test method. (A) Adapted from [13], (B) adapted from [18], (C, D) developed 
from [11, 12].
Figure 1
A comparison among the current views of the adverse outcome pathway (AOP), including mode of action and pathway of toxicity 
(A), the TiPED Tiered Protocol for Endocrine Disruption (B), and the LIFE-EDESIA animal-free Endocrine Disruptor (ED) screening 
strategy (C, D). LIFE-EDESIA in silico-in vitro ED screening strategy starts from a virtual screening (C) to proceed through the use 
of multiple cell-specific, ED-targeted, functional assays making use of biomarkers of effect derived from clinical biomarkers (D).















docrinologyas well  as with  the majority  of  findings  in 







a  cost-effective  generation  of  comprehensive  hazard 
data sets on a large number of chemicals: this will meet 
the  general  aim of  the European Regulation REACH 
(2006/1907/EC) as well as major  issues  in  the field of 
food  safety  (emerging  contaminants,  residues  and  en-
vironmental by-products of pesticides,  etc.). However, 


















started from the statement that “an adverse ...effect can be 
described by a series of causally linked biochemical or bio-








is  just  one,  albeit  necessary,  component  of  the  AOP, 
which builds up  through a  cascade of  intermediate or 
key events at  the subcellular, cellular,  tissue and/or or-
gan level leading to a specific adverse outcome (AO) at 
the  individual or population  level  [3]. Another  related 
framework is that of pathways of toxicity (PoT) (Figure 
















[11-13 and  refs  therein] might be  the missing  link  to 
connect  mechanistic  endpoints  to  well-defined  and 
measurable in vitro endpoints that are directly relevant 




















secretion)  depends  on  the  intermediate  events  occur-
ring at the organelle level: for instance, in LNCaP cell 
line  the  intracellular  localization  of  the  ED-activated 
AR is different when different anti-androgens are used. 
In  comparison  to DHT,  indeed, man-made chemicals 




tion  in LNCaP cells  constitutes  an  alternative  trigger 
of a MoA or AOP resulting, as tissue effect and organ 
response, in a reduced semen quality, that is one TDS 




LIFE-EDESIA  (LIFE12  ENV/IT/000633;  www.iss.
it/life),  a  project  granted within  the  frame of  the EU 
LIFE Environment program, aims to demonstrate the 




REACH  Regulation),  but  still  widely  used,  the  plas-
ticizers  phthalates  and  bisphenols.  In  addition  LIFE-
EDESIA considers also parabens, antimicrobial preser-
vatives widespread used in cosmetics, pharmaceuticals 



























docking  to  quantitative-structure  activity  relationship 
(QSAR)  (Figure 1C).  In  the  ensuing  step,  chemicals 




resentative  of  endocrine-targeted human  tissues. ED-
relevant effects are assessed by measuring cell-specific, 
biomarkers of effect (Figures 1C-D) that show the cel-









spectively  (www.iss.it/life)  (Figure 1D). Noticeably,  this 
experimental  approach  largely  overlaps with  a  recently 
proposed  Tiered  Protocol  for  Endocrine  Disruption 
(TiPED) (Figure 1B) [18] aimed to support green chem-
istry in the design of new and less hazardous chemicals.
The  LIFE-EDESIA  strategy  ultimately  implements 
an  AOP-derived  approach  from  in silico  NR  binding 
through to clinically relevant  functional biomarkers of 
endocrine disruption.
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AR: androgen receptor; ED: endocrine disruptor; KLK: kallikrein; NR: nuclear receptor; PSA: prostate-specific antigene. (A) developed from [11, 12], (B) adapted from 
[14], and (C) adapted from [13]
Figure 2
Integrating the LIFE-EDESIA endocrine-based screening (A) using cell-specific, ED-targeted functional assays and biomarkers with-
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